DRESS syndrome natural history, complications and prognosis

DRESS syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating DRESS syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
DRESS syndrome On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of DRESS syndrome All Images syndrome X-ray X-rays syndrome Ultrasound Echo & Ultrasound syndrome CT CT Images syndrome MRI MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on DRESS syndrome
CDC on DRESS syndrome
DRESS syndrome in the news
Blogs on DRESS syndrome
Directions to Hospitals Treating DRESS syndrome
Risk calculators and risk factors for DRESS syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

DRESS syndrome is characterized by a prolonged latency period (2-8 weeks following the administration of triggering drug). If left untreated, DRESS syndrome self-resolves following the discontinuation of the triggering drug in the majority of cases, but clinical manifestations may persist up to 3 months and the long-term sequelae have not yet been identified. Complications of DRESS syndrome include visceral organ involvement and long-term autoimmune diseases. The prognosis of DRESS syndrome is generally good, and the case-fatality rate is approximately 10%. Factors associated with worse prognosis have not yet been established.

Natural History

• DRESS syndrome is characterized by a prolonged latency period.
• Clinical manifestations of DRESS syndrome are usually delayed. Earliest manifestations may appear 2-8 weeks following the administration of triggering drug.
• Initially, patients usually develop non-specific signs and symptoms, namely fever and rash, making the early diagnosis of DRESS syndrome difficult upon patient presentation.
• Additional clinical manifestations follow, and patients may subsequently develop lymphadenopathy, visceral disease (typically liver involvement), and worsening of the skin eruption.
• The nature of the visceral involvement is thought to be associated with the identity of the triggering drug:

• Hepatic and GI involvement has been associated with abacavir
• Renal involvement has been associated with allopurinol
• Pulmonary involvement has been associated with abacavir and minocycline

• If left untreated, DRESS syndrome self-resolves following the discontinuation of triggering drug in the majority of cases, but clinical manifestations may persist up to 3 months and the long-term sequelae have not yet been identified.

Complications

• Organ involvement is considered the most important complication of DRESS syndrome.
• Complications of DRESS syndrome include the following:

• Hepatitis and hepatic necrosis
• Interstitial nephritis
• Chronic kidney disease
• Pneumonitis
• Eosinophilic pneumopathy
• Carditis
• Encephalopathy
• Pleuritis
• Pericarditis
• Myopathy
• Pancreatitis
• Thyroiditis

• Long term complications often include the development of autoimmune diseases, such as:
• Autoimmune hemolytic anemia
• Graves' disease
• Insulin-dependent diabetes mellitus

Prognosis

• The prognosis of DRESS syndrome is generally good.
• The case-fatality rate of DRESS syndrome is approximately 10%. Mortality is most commonly due to fulminant hepatic failure.
• Factors associated with worse prognosis of DRESS syndrome have not yet been established. Early drug discontinuation has been suggested as a favorable prognostic factor.
• Administration of corticosteroid therapy has not been demonstrated to be associated with reduced risk of death, , but patients who do not undergo slow corticosteroid tapering (over several weeks) are thought to be at an increased risk of relapse.